As of October 22, 2026, Zymeworks Inc. Common Stock (ZYME) trades at $27.87. No model fair value is published for ZYME. Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For ZYME they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown.
Source: Equity Rank — ZYME valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Zymeworks Inc. Common Stock (ZYME) is next scheduled to report earnings on Nov 5, 2026. The consensus analyst EPS estimate for the upcoming quarter is $2.50.
Reported EPS came in above the analyst estimate in 4 of the last 8 reports. The median share-price change across a report, in either direction, was 2.4%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.56 | $-0.62 | -10.7% | +1.8% |
| May 7, 2026 | $-0.10 | $-0.59 | -490.0% | -10.2% |
| Mar 2, 2026 | $-0.32 | $-0.55 | -70.6% | +0.1% |
| Nov 6, 2025 | $-0.32 | $-0.26 | +18.8% | -8.0% |
| Aug 7, 2025 | $-0.52 | $0.03 | +105.8% | -1.1% |
| May 8, 2025 | $-0.70 | $-0.30 | +57.1% | -0.1% |
| Mar 5, 2025 | $-0.09 | $-0.31 | -236.2% | +3.4% |
| Oct 31, 2024 | $-0.41 | $-0.39 | +4.9% | -3.1% |
Equity Rank computed model fair value for ZYME from 2 independent valuation methods with sufficient data. 1 place fair value above the current price of $27.87, and 1 place it below. No blended model fair value is published for this company. The methods are evenly split, reflecting genuine dispersion in the estimate.
Equity Rank's fundamental strength composite scores ZYME at 46.3/100 (C, Adequate), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved +40.4 pp. Its SAVE composite score has moved +0.0 over the past 30 days.
Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For ZYME they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown. Informational only — not investment advice.
Zymeworks Inc. Common Stock (ZYME) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Zymeworks Inc. Common Stock (ZYME) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/ZYME. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.